Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

Exclusion Criteria

• •Subject has received anti-cancer therapy within 21 days or within a period defined by 5 half lives, whichever is shorter, prior to study drug administration.
• •Subject has untreated brain or meningeal metastases.
• •Subject has received a tyrosine kinase inhibitor (TKI) other than sunitinib or sorafenib.
• •Prior use of Avastin is allowed.
• •The subject is receiving therapeutic anticoagulation therapy.
• •The subject has a history of/or currently exhibits clinically significant cancer related events of bleeding (e.g., hematuria, hemoptysis).
• •The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (BP) \> 100 mmHg; or systolic blood pressure (BP) \> 150 mmHg.
• •The subject has a history of myocardial infarction within 6 months of Study Day 1.
• •The subject has a documented left ventricular (LV) Ejection Fraction \< 50%.
• •The subject has known autoimmune disease with renal involvement (eg, Lupus).
• •Female subjects who are pregnant or breast feeding.
• •Subject is receiving anti-retroviral therapy for HIV.
• •Subject has a clinically significant uncontrolled condition(s) including but not limited to:
• •* active uncontrolled infection,
• •* Class III or IV heart failure as defined by the New York Heart Association functional classification system,
• •* unstable angina pectoris or cardiac arrhythmia,
• •* history of adrenal insufficiency,
• •* psychiatric illness/social situation that would limit compliance with study requirements;
• •* Active, ulcerative colitis, Crohn's disease, celiadisease or any other conditions that interfere with absorption.
• •* Subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.